| The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non–small cell lung cancer T Hakozaki, C Richard, A Elkrief, Y Hosomi, M Benlaïfaoui, I Mimpen, ... Cancer Immunology Research 8 (10), 1243-1250, 2020 | 201 | 2020 |
| Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer T Hakozaki, Y Okuma, M Omori, Y Hosomi Oncology Letters 17 (3), 2946-2952, 2019 | 118 | 2019 |
| Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: case series … S Kitagawa, T Hakozaki, R Kitadai, Y Hosomi Thoracic Cancer 11 (7), 1927-1933, 2020 | 64 | 2020 |
| Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real … A Desilets, F Blanc-Durand, S Lau, T Hakozaki, R Kitadai, J Malo, ... European Journal of Cancer 142, 83-91, 2021 | 61 | 2021 |
| Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study M Omori, Y Okuma, T Hakozaki, Y Hosomi Molecular and clinical oncology 10 (1), 137-143, 2019 | 60 | 2019 |
| The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases R Kitadai, Y Okuma, T Hakozaki, Y Hosomi Journal of Cancer Research and Clinical Oncology 146, 777-785, 2020 | 48 | 2020 |
| A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors FY Shaikh, JR White, JJ Gills, T Hakozaki, C Richard, B Routy, Y Okuma, ... Clinical Cancer Research 27 (9), 2571-2583, 2021 | 35 | 2021 |
| Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy T Hakozaki, Y Hosomi, A Shimizu, R Kitadai, K Mirokuji, Y Okuma Journal of Cancer Research and Clinical Oncology 146, 2659-2668, 2020 | 29 | 2020 |
| The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. Cancer Immunol. Res. 2020; 8: 1243–1250. doi: 10 … T Hakozaki, C Richard, A Elkrief, Y Hosomi, M Benlaïfaoui, I Mimpen, ... CIR-20-0196.[Abstract][CrossRef][Google Scholar], 0 | 29 | |
| Cancer cachexia among patients with advanced non-small-cell lung cancer on immunotherapy: an observational study with exploratory gut microbiota analysis T Hakozaki, A Nolin-Lapalme, M Kogawa, Y Okuma, S Nakamura, ... Cancers 14 (21), 5405, 2022 | 22 | 2022 |
| Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients J Feng, Y Li, B Wei, L Guo, W Li, Q Xia, C Zhao, J Zheng, J Zhao, R Sun, ... Translational Lung Cancer Research 11 (4), 617, 2022 | 20 | 2022 |
| Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report T Hakozaki, Y Okuma, J Kashima BMC cancer 18, 1-4, 2018 | 20 | 2018 |
| Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer T Hakozaki, Y Hosomi, R Kitadai, S Kitagawa, Y Okuma Journal of Cancer Research and Clinical Oncology 146, 2957-2966, 2020 | 18 | 2020 |
| Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors T Hakozaki, T Matsuo, A Shimizu, Y Ishihara, Y Hosomi Journal of Geriatric Oncology 12 (1), 64-71, 2021 | 17 | 2021 |
| A multicenter, randomized phase III study comparing platinum combination chemotherapy plus pembrolizumab with platinum combination chemotherapy plus nivolumab and ipilimumab … Y Shiraishi, T Hakozaki, S Nomura, T Kataoka, K Tanaka, S Miura, ... Clinical Lung Cancer 23 (4), e285-e288, 2022 | 16 | 2022 |
| Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations Y Uehara, K Watanabe, T Hakozaki, M Yomota, Y Hosomi Thoracic Cancer 13 (11), 1703-1711, 2022 | 11 | 2022 |
| Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in … Y Uehara, T Hakozaki, R Kitadai, K Narita, K Watanabe, K Hashimoto, ... Translational Lung Cancer Research 11 (2), 135, 2022 | 10 | 2022 |
| Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study D Zhang, Y Shi, X Liu, J Liu, Y Xu, J Zhao, W Zhong, L Käsmann, ... Translational Lung Cancer Research 11 (7), 1420, 2022 | 9 | 2022 |
| Combined small and squamous transformation in EGFR-mutated lung adenocarcinoma T Hakozaki, M Kitazono, M Takamori, T Kiriu Internal Medicine 59 (10), 1291-1294, 2020 | 9 | 2020 |
| Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer C Shao, K Guo, L Xu, Y Zhang, H Duan, Y Feng, M Pan, D Lu, X Ren, ... Translational Lung Cancer Research 10 (12), 4558, 2021 | 7 | 2021 |
